Oseltamivir/pimodivir

Drug Profile

Oseltamivir/pimodivir

Alternative Names: JNJ-63623872/Oseltamivir; Pimodivir/oseltamivir; VX 787/oseltamivir

Latest Information Update: 06 Jul 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Janssen-Cilag
  • Class Acetamides; Antivirals; Cyclohexanes; Cyclohexenes; Esters; Small molecules
  • Mechanism of Action Neuraminidase inhibitors; Viral protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I Influenza A virus infections

Most Recent Events

  • 06 Jul 2017 Chemical structure information added
  • 14 Apr 2017 Janssen-Cilag completes a phase I trial in Influenza-A virus infections (In volunteers) in Belgium (PO) (NCT03023852)
  • 14 Feb 2017 Phase-I clinical trials in Influenza-A virus infections (In volunteers) in Belgium (PO) (NCT03023852)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top